E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid |
|
E.2.2 | Secondary objectives of the trial |
1. drug safety of nasal Tobramycin (only for pilot-study) - Serum levels in non-toxic range - mucosal tolerance 2. Changes of the Sino-nasal-outcome test SNOT-20 adapt CF / patient`s diary 3. detection of P. aeruginosa in sputum / througt swap 4. Genotyping of P. aeruginosa 5. Changes in rhinoscopic findings (size of polyps, mucosa, secretions) 6. Changes in rhinomanometric findings (pilot study) 7. Cytology, Cytokines in nasal lavage 8. Incidence of rhinosinusitic and pulmonal exazerbations |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject has a confirmed diagnosis of cystic fibrosis based on: 3 positive sweat chloride tests and/or genetic characterisation 2. detection of P. aeruginosa in nasal lavage (culture) with chronic P. aeruginosa colonization of the lung (from day – 28) 3. informed consent of the patients or parents 4. Subject is older than 7 years 5. Subject is able to comply with the inhalation procedures and nasal lavage procedures scheduled in the protocol. 6. Women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol (e.g. implants, combined oral contraceptives, injectables, some IUDs, sexual abstinence or vasectomised partner) |
|
E.4 | Principal exclusion criteria |
1. subject has a critical condition defined as: FEV1 < 30% and / or SaO2 < 93% without O2-substitution; need of O2-substitution 2. Subject had an ENT surgery within 3 months prior to study 3. Subject shows signs of nasal bleeding 4. Subject has an ear drum perforation 5. Subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy against pseudomonas aerug. 6. Subject is unlikely to comply with the procedures scheduled in the protocol 7. Subject has a known allergic reaction to the medication 8. Subject is pregnant or breastfeeding 9. Subject participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study. 10. Systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the inclusion and during the study 11. If serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to withdraw the participation in the study. 12. progressed renal insufficiency 13. severe damage of the N. acusticus 14. dissiness (potential damage of N. vestibularis) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be reached, when the last subject completes his last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |